menu
    • menu
    [{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Firibastat","moa":"APA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Not Applicable"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Firibastat","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Quantum Genomics \/ qilu pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ qilu pharmaceutical"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Firibastat","moa":"APA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Faran","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Firibastat","moa":"APA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Faran","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Faran"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Firibastat","moa":"APA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Not Applicable"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Firibastat","moa":"APA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Not Applicable"},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Firibastat","moa":"Glutamyl aminopeptidase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Quantum Genomics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Genomics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Firibastat

    Menu

    Firibastat

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase III Study, FRESH And Is ...

                            Details : The firibastat (originally named QGC001) product, a BAPAI candidate-drug, is a prodrug that delivers in the brain the EC33 product, a selective and specific inhibitor of Aminopeptidase A, thus preventing the production of Angiontensin III in the brain.

                            Brand Name : QGC001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 28, 2022

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quantum Genomics To Present Top-line Results From its QUORUM Study of Firibastat in Heart Failure Post Myocard...

                            Details : The aim of the study is to assess the efficacy and the safety of firibastat compared to ramipril. The primary endpoint is the change from baseline in Left Ventricle Ejection Fraction (LVEF) assessed by Cardiac Magnetic Resonance (CMR) after a three-month...

                            Brand Name : QGC001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 21, 2021

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quantum Genomics Launches Phase III Pivotal REFRESH Study in Resistant Hypertension with Once-a-day Formulatio...

                            Details : Phase III Pivotal REFRESH Study is part of firibastat’s Phase III clinical development and aims to assess long-term safety as well as the three-month efficacy after a single daily dose of firibastat 1000mg in treatment resistant hypertensive patients.

                            Brand Name : QGC001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 18, 2021

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Faran

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran

                            Details : Under the terms of the agreement, Faran will receive the exclusive rights to market Firibastat for the treatment of difficult-to-treat / resistant hypertension in Greece.

                            Brand Name : QGC001

                            Molecule Type : Small molecule

                            Upfront Cash : $12.1 million

                            December 15, 2020

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Faran

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Xediton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals

                            Details : Under the terms of the agreement, Xediton Pharmaceuticals will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Canada.

                            Brand Name : QGC001

                            Molecule Type : Small molecule

                            Upfront Cash : $11.3 million

                            October 28, 2020

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Xediton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Qilu Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical

                            Details : Under the terms of the agreement, Qilu Pharmaceutical will receive the exclusive rights to market firibastat for the treatment of difficult-to-treat / resistant hypertension in China, including Hong Kong and Macau.

                            Brand Name : QGC001

                            Molecule Type : Small molecule

                            Upfront Cash : $50.0 million

                            October 19, 2020

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Qilu Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed

                            Quantum Genomics

                            France arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-trea...

                            Details : First patient in the Company’s FRESH study (Firibastat in treatment-RESistant Hypertension) in difficult-to-treat(1) or resistant(2) hypertension. The study is being conducted jointly with its partner in Latin America, the Biolab Sanus Pharmaceutical l...

                            Brand Name : QGC001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 13, 2020

                            Lead Product(s) : Firibastat

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth